Cingulate therapeutics filing

Author: xcff

August undefined, 2024

WebCingulate Therapeutics is a Biotechnology, Pharmaceuticals, and Pharmaceutical Manufacturing company located in Morristown, New Jersey with $2.00 Million in revenue and 14 employees. Find top employees, contact details and business statistics at RocketReach. ... (28 currently) – along with the filing of multiple provisional applications ... WebUncategorized (1) Contracts. Master Services Agreement between Cingulate Therapeutics LLC and Societal CDMO, Inc., dated October 24, 2024 (Filed With SEC on October 25, 2024) Promissory Note, dated August 9, 2024, between Cingulate Therapeutics, LLC and Werth Family Investment Associates LLC (Filed With SEC on August 11, 2024) …

Cingulate Inc. S-1 filing (2024-09-09) wallmine

WebCingulate currently has two (2) product candidates, CTX-1301 and CTX-1302, that are being developed to serve the approximate $18 billion annual U.S. ADHD market. A third product candidate, CTX-2103, is being developed to serve the roughly $5 billion U.S. … 10 Mar 2024 Cingulate Inc. Reports Fourth Quarter and Full Year 2024 Financial … Pipeline Overview. Cingulate® completed a proof-of-concept trial in human subjects … Cingulate Inc. 1901 W 47th Place Kansas City, KS 66205 (913) 942-2300 … Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and … About Cingulate®. Cingulate® (CTx®)is a Phase 3 clinical stage … Mr. Gallagher is a Co-Founder of Cingulate Therapeutics and serves as a member … The Investor Relations website contains information about Cingulate Inc's … WebMar 31, 2024 · The transplantation of neural progenitors into a host brain represents a useful tool to evaluate the involvement of cell-autonomous processes and host local cues in the regulation of neuronal differentiation during the development of the mammalian brain. Human brain development starts at the embryonic stages, in utero, with unique … billy knight boxer

Cingulate Therapeutics Announces $7.5M Equity Investment …

WebJul 10, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both products in the first quarter of 2024 and will pursue approval via the accelerated 505 (b)(2) regulatory pathway. ... WebCingulate Inc. Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation ... WebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva; Cingulate Inc. Reports First Quarter 2024 Results and Provides Clinical and Business Update Announcement of First Subject Dosing for Anxiety Candidate CTx-2103 to Extend the Application of the Precision Timed Release™ … billy knight

Cingulate Inc. Announces Pricing of $25.0 Million Initial Public …

Cingulate therapeutics filing

SEC Info - Cingulate Therapeutics - ‘D/A’ on 7/3/19

Did you know?

WebJul 11, 2024 · About Cingulate Therapeutics ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the accelerated 505(b)(2) regulatory ... WebMar 10, 2024 · Inside Cingulate Inc.'s 10-K Annual Report: Financial - Expense Highlight. We have experienced, and will continue to experience, increased expenses associated …

WebApr 6, 2024 · Alterity Therapeutics NASDAQ:ATHE; View All Competitors. Insiders & Institutions. HighTower Advisors LLC Bought 34,425 shares on 2/9/2024 Ownership: … WebCingulate Therapeutics is based out of Morristown. The firm last filed a Form D notice of exempt offering of securities on 2024-06-29. The notice included securities offered of …

WebCINGULATE THERAPEUTICS LLC. CINGULATE INC. AND. CINGULATE PHARMA LLC. DATED AS OF AUGUST 30, 2024 . ... 2024, which in turn formed Merger Sub by filing … WebApr 2, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the accelerated 505(b)(2) regulatory ...

WebThe Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. ... Cingulate Therapeutics: Street Address 1 Street Address 2; 1901 W. 47th Place: SUITE 300: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; KANSAS CITY: … billy knight basketball referenceWebAmendment to Employment Agreement, effective April 1, 2024, between Cingulate Therapeutics LLC and Raul R. Silva; Cingulate Inc. Reports First Quarter 2024 Results … billy k montrealWebSep 9, 2024 · Cingulate Inc. S-1 Filing information. Filed on 9 September 2024 SEC Edgar 000149315221022284 Exhibits & attachments & exports. ... Top menu > File > Make a copy... Copy & paste the following URL into the D2 cell: Do you need help with the setup? Let us know at [email protected]. Close. cyndie thouveninWebSep 14, 2024 · Cingulate, Inc. ( NASDAQ: CING) is a clinical-stage biopharmaceutical company with a proprietary Precision Timed Release (PTR) drug delivery platform … cyndie lee photography wiWebApr 2, 2024 · About Cingulate Therapeutics. ... Cingulate anticipates filing INDs for both assets in the third and fourth quarters of 2024 and will pursue approval via the … cyndie on the walking deadWebSep 24, 2014 · Somerset, N.J. – September 24, 2014 — Catalent Pharma Solutions has reached an exclusive development and licensing agreement with privately held biopharmaceutical company, Cingulate Therapeutics (CTx), to support the development of a series of new prescription pharmaceutical products for the treatment of Attention … billy knife in predatorWebCINGULATE THERAPEUTICS LLC: TEXAS FOREIGN LIMITED-LIABILITY COMPANY (LLC) WRITE REVIEW: Address: 1901 W. 47th Place, Ste 310 Kansas City, KS 66205: Registered Agent: C T Corporation System: Filing Date: June 06, 2024: File Number: 0803337838: Contact Us About The Company Profile For Cingulate Therapeutics LLC billy knightly